NewsOctober 25
Announcement of New Appointments of PHC Group Corporate Executives
Tokyo, October 25, 2019 - PHC Holdings Corporation (headquarters: Tokyo, Japan) announces the appointment of PHC Group’s corporate executives that will be effective from October 15, 2019. They will be responsible for key corporate functions and business domains across the PHC Group, in an optimized organizational set-up, designed to create synergies and cost efficiencies following the recent acquisitions.
Michael Kloss, President and CEO of PHC Holdings Corporation, explained, “Following the close of the recent acquisitions of the anatomical pathology business from Thermo Fisher Scientific (currently operating as Epredia) and LSI Medience from Life Science Institute, Inc., PHC Group is now in the next transformative phase of its development. As we began to integrate these new businesses, we needed to find the best way to bring them together to generate value and drive revenue for our group. We believe that the new organizational set-up we have created with the appointment of these corporate officers will establish the optimum set-up to enable us to deliver on our growth ambitions. It will allow us to create synergies, be agile and find efficiencies that will enable further investment into exciting areas of innovation. This will be key as we continue on our journey to become the leading provider of best-in-class precision and digital solutions in Diagnostics and Life Sciences globally and Healthcare Services in Japan.”
About PHC Holdings Corporation
Incorporated in 2014, PHC Holdings Corporation is a global healthcare company with its subsidiaries including PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia and LSI Medience. Committed to its corporate mission, “We contribute to the wellbeing of society through our diligent efforts to create healthcare solutions that have a positive impact and improve the lives of people,” the company develops, manufactures, sells and services medical equipment and solutions across diabetes management, diagnostics, life sciences and healthcare services. PHC Holdings Corporation group’s consolidated net sales in FY2018 was 186.8 billion yen with global distribution of products and services for more than 125 countries.
For further information on PHC Holdings Corporation, please visit
www.phchd.com
PHC Holdings Corporation
1. Changes to the Roles and Responsibilities on October 15, 2019
| Name |
Until Oct.14, 2019 |
From Oct.15, 2019 |
| Ryuichi Hirashima |
Corporate Officer,
Chief Strategic Officer(CSO),
Corporate Planning,
BPR Promotion,
and Business Development
(Concurrent assignment as) General Manager,
Business Development Department |
Corporate Officer,
Chief Strategic Officer(CSO),
Corporate Planning,
Business Development and External Affairs
(Concurrent assignment as) General Manager,
Business Development Department |
| Norio Ubukata |
Corporate Officer,
Chief Risk Officer (CRO) |
Corporate Officer,
General Counsel |
| Ryuji Nakashima |
Corporate Officer,
Chief Human Resource Officer (CHRO),
Chief Administration Officer (CAO) |
Corporate Officer,
Japan HR Head,
Chief Administration Officer (CAO) |
2. New Appointments of Corporate Officers in PHC Holdings Corporation on October 15, 2019
| Position/Title |
Name |
Remarks |
Corporate Officer,
Chief Transformation Officer (CTRO) |
Peter Eckenberg |
|
Corporate Officer,
Head of Diabetes Management
Business Domain |
Robert Schumm |
|
Corporate Officer,
International HR Head |
Myra Rosen |
|
Corporate Officer,
Engineering, and Manufacturing |
Kyoji Morimoto |
|
3. Board of Directors at PHC Holdings Corporation on October 15, 2019
| Position/Title |
Name |
Remarks |
President,
Member of Board,
Chief Executive Officer (CEO) |
Michael Kloss |
President,
Ascensia Diabetes Care Holdings AG |
Executive Vice President,
Member of Board,
Chief Operating Officer (COO) |
Shoji Miyazaki |
President,
PHC Corporation |
Director,
Member of Board |
Hirofumi Hirano |
President,
KKR Japan Limited |
Director,
Member of Board |
Eiji Yatagawa |
Partner,
KKR Japan Limited |
Director,
Member of Board |
Hidekazu Tanaka |
General Manager,
Healthcare Business Div.
Healthcare & Service Business Unit
MITSUI & CO., LTD. |
Director,
Member of Board |
Koichiro Sato |
General Manager,
Healthcare Business 3rd Dept.
Healthcare Business Div.
Healthcare & Service Business Unit
MITSUI & CO., LTD. |
Director,
Member of Board |
Tatsunobu Fukushima |
General Manager,
Corporate Planning Department
Life Science Institute, Inc. |
| Corporate Auditor |
Koichi Ikeuchi |
Corporate Auditor,
PHC Corporation |
Corporate Auditor
(Independent outside auditor) |
Noriaki Yamada |
Clifix Certified Public Tax Accountant’s Corporation |
| Corporate Auditor |
Ken Matsumura |
Principal,
KKR Japan Limited |
| Corporate Auditor |
Atsushi Shibata |
Manager,
Healthcare Business 3rd Dept.
Healthcare Business Div.
Healthcare & Service Business Unit
MITSUI & CO., LTD. |
| Corporate Auditor |
Tatsuo Kuwajima |
Corporate Auditor,
Life Science Institute, Inc. |
Corporate Officer,
Chief Financial Officer (CFO) |
Frederick Reidenbach |
|
Corporate Officer,
Chief Strategic Officer (CSO),
Corporate Planning,
Business Development and External Affairs
(Concurrent assignment as) General Manager,
Business Development Department |
Ryuichi Hirashima |
|
Corporate Officer,
Chief Transformation Officer (CTRO) |
Peter Eckenberg |
|
Corporate Officer,
Head of Diabetes Management
Business Domain |
Robert Schumm |
|
Corporate Officer,
General Counsel |
Norio Ubukata |
|
Corporate Officer,
Chief Information Officer (CIO) |
Takashi Mineshima |
|
Corporate Officer,
for Special Missions,
Healthcare IT Alliance |
Noboru Ohrui |
|
Corporate Officer,
Japan HR Head,
Chief Administration Officer (CAO) |
Ryuji Nakashima |
|
Corporate Officer,
International HR Head |
Myra Rosen |
|
Corporate Officer,
Engineering, and Manufacturing |
Kyoji Morimoto |
|
4. PHC Group Executive Committee members on October 15, 2019
| Position/Title |
Name |
Remarks |
President,
Member of Board,
Chief Executive Officer (CEO) |
Michael Kloss |
|
Executive Vice President,
Member of Board,
Chief Operating Officer (COO) |
Shoji Miyazaki |
|
| Corporate Auditor |
Koichi Ikeuchi |
|
Corporate Officer,
Chief Financial Officer (CFO) |
Frederick Reidenbach |
|
Corporate Officer,
Chief Strategic Officer (CSO),
Corporate Planning, Business Development and External Affairs
(Concurrent assignment as) General Manager,
Business Development Department |
Ryuichi Hirashima |
|
Corporate Officer,
Chief Transformation Officer (CTRO) |
Peter Eckenberg |
|
Corporate Officer,
Head of Diabetes Management
Business Domain |
Robert Schumm |
|
Corporate Officer,
General Counsel |
Norio Ubukata |
|
Corporate Officer,
Japan HR Head,
Chief Administration Officer (CAO) |
Ryuji Nakashima |
|
Corporate Officer,
International HR Head |
Myra Rosen |
|
| Head of Anatomical Pathology Business Unit |
James Post |
|
5. Board of Directors Meeting Attendees at PHC Holdings Corporation on October 15, 2019
| Position/Title |
Name |
Remarks |
President,
Member of Board,
Chief Executive Officer (CEO) |
Michael Kloss |
President,
Ascensia Diabetes Care Holdings AG |
Executive Vice President,
Member of Board,
Chief Operating Officer (COO) |
Shoji Miyazaki |
President,
PHC Corporation |
Director,
Member of Board |
Hirofumi Hirano |
President,
KKR Japan Limited |
Director,
Member of Board |
Eiji Yatagawa |
Partner,
KKR Japan Limited |
Director,
Member of Board |
Hidekazu Tanaka |
General Manager,
Healthcare Business Div.
Healthcare & Service Business Unit
MITSUI & CO., LTD. |
Director,
Member of Board |
Koichiro Sato |
General Manager,
Healthcare Business 3rd Dept.
Healthcare Business Div.
Healthcare & Service Business Unit
MITSUI & CO., LTD. |
Director,
Member of Board |
Tatsunobu Fukushima |
General Manager,
Corporate Planning Department
Life Science Institute, Inc. |
| Corporate Auditor |
Koichi Ikeuchi |
Corporate Auditor,
PHC Corporation |
Corporate Auditor
(Independent outside auditor) |
Noriaki Yamada |
Clifix Certified Public Tax Accountant’s Corporation |
| Corporate Auditor |
Ken Matsumura |
Principal,
KKR Japan Limited |
| Corporate Auditor |
Atsushi Shibata |
Manager,
Healthcare Business 3rd Dept.
Healthcare Business Div.
Healthcare & Service Business Unit
MITSUI & CO., LTD. |
| Corporate Auditor |
Tatsuo Kuwajima |
Corporate Auditor,
Life Science Institute, Inc. |
Corporate Officer,
Chief financial Officer (CFO) |
Frederick Reidenbach |
|
Corporate Officer,
Chief Strategic Officer (CSO),
Corporate Planning,
Business Development and External Affairs
(Concurrent assignment as) General Manager,
Business Development Department |
Ryuichi Hirashima |
|
Corporate Officer,
Chief Transformation Officer (CTRO) |
Peter Eckenberg |
|
Corporate Officer,
Head of Diabetes Management Business Domain |
Robert Schumm |
|
| Corporate Officer, General Counsel |
Norio Ubukata |
|
Corporate Officer,
Japan HR head,
Chief Administration Officer (CAO) |
Ryuji Nakashima |
|
Corporate Officer,
International HR head |
Myra Rosen |
|
PHC Corporation
1. Changes to the Roles and Responsibilities at PHC Corporation on October 15, 2019
| Name |
Until Oct.14, 2019 |
From Oct.15, 2019 |
| Yuji Maruhashi |
Member of Board,
Administration,
General Manager,
Corporate Accounting Department |
Member of Board,
Administration,
(concurrent assignment as) Union and Labor Relations,
General Manager,
Corporate Accounting Department |
| Osamu Takahashi |
Member of Board,
General Manager,
Medical Policy & Public Affairs Department
(concurrent assignment as) Technology Planning Department |
Member of Board,
General Manager,
Medical Policy & Public Affairs Department |
2. Board of Directors at PHC Corporation on October 15, 2019
| Position/Title |
Name |
Responsibility |
President,
Member of Board |
Shoji Miyazaki |
|
Director,
Member of Board |
Yuji Maruhashi |
Member of Board,
Administration,
(concurrent assignment as) Union and Labor Relations,
General Manager,
Corporate Accounting Department |
Director,
Member of Board |
Osamu Takahashi |
General Manager,
Medical Policy & Public Affairs Department |
Director,
Member of Board |
Takayuki Otsuka |
Director,
Medical Information Systems Division |
Director,
Member of Board |
Nobuaki Nakamura |
Director,
Biomedical Division |
| Corporate Auditor |
Koichi Ikeuchi |
|